Using quality-adjusted progression-free survival as an outcome measure to assess the benefits of cancer drugs in randomized-controlled trials: case of the BOLERO-2 trial.

Diaby V, Adunlin G, Ali AA, Tawk R. Using quality-adjusted progression-free survival as an outcome measure to assess the benefits of cancer drugs in randomized-controlled trials: case of the BOLERO-2 trial. Breast Cancer Res Treat. 2014 Aug; 146(3):669-73.

View in: PubMed

subject areas

Androstadienes
Antineoplastic Combined Chemotherapy Protocols
Breast Neoplasms
Disease-Free Survival
Female
Humans
Receptor, erbB-2
Receptors, Estrogen
Receptors, Progesterone
Sirolimus
Thiocarbamates
Treatment Outcome

authors with profiles

Rima Tawk
Vakaramoko Diaby

RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support